Companies: 10,795·Total market cap: $144.5T
iBio, Inc.

iBio, Inc.

IBIONASDAQHealthcare● Active
$1.76
+$0.03(+1.45%)
Market Cap$27710525
P/E Ratio
52W High$3.82
52W Low$0.56

iBio, Inc. (IBIO) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

ibio · pe ratio · data through Jun 30, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for iBio, Inc. (IBIO) measures how much investors pay for each dollar of the company's trailing earnings. IBIO's current PE ratio of N/A is calculated by dividing its stock price of $1.75 by its TTM earnings per share of -$0.23.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30

Forward P/E
N/A
FY2027 est. EPS $-0.32
Based on 3 analysts
EPS (TTM)
-$0.23
TTM · diluted EPS
PEG Ratio
-0.04
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · iBio, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2007 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
iBio, Inc.
iBio, Inc.You
IBIO
$28MN/A-$0.23
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc.
ANTX
$105MN/A-$1.16
Boundless Bio, Inc.
Boundless Bio, Inc.
BOLD
$32MN/A-$2.60
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$12MN/A-$6.64
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.
INTS
$7MN/A-$0.86
Iterum Therapeutics plc
Iterum Therapeutics plc
ITRM
$2MN/A-$1.26
Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc.
KLTO
$20MN/A-$0.32

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 19 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-06-30Latest
FY2025
$-1.75
2024-06-30
FY2024
$-6.50
2023-06-30
FY2023
$-106.18
2022-06-30
FY2022
$-2889.06
2021-06-30
FY2021
$-59.32
2020-06-30
FY2020
$-130.89
2019-06-30
FY2019
$-464.78
2018-06-30
FY2018
$-757.45
2017-06-30
FY2017
$-815.40
2016-06-30
FY2016
$-602.94

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for iBio, Inc. (IBIO) measures how much investors pay for each dollar of the company's trailing earnings. IBIO's current PE ratio of N/A is calculated by dividing its stock price of $1.75 by its TTM earnings per share of -$0.23.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.75 ÷ -$0.23 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

IBIO pe ratio · 6 questions

IBIO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.75 and TTM EPS of -$0.23. Data sourced from Financial Modeling Prep via IBIO's SEC 10-K and 10-Q filings.

IBIO PE ratioWhat is IBIO PE ratioCurrent PE ratio of IBIOIBIO PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · iBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09